[The effect of ipratropium bromide on lung function in patients with cystic fibrosis]

Pneumologie. 1990 Feb;44 Suppl 1:277-8.
[Article in German]

Abstract

The main manifestation of cystic fibrosis (CF) of the lungs is an obstructive ventilation disturbance. The fact that the administration of atropine improves pulmonary function in patients with CF suggests a vagal mechanism for the development of bronchal obstruction. In a single-blind, placebo-controlled study, we investigated the effect of 250 micrograms of an inhalation solution of the anticholinergic substance ipatropium bromide (IB) on the pulmonary function of 11 patients with CF (age range: 8 to 29 years). The mean figures for the changes in FEV1.0, FEF25-75%, RV and TLC after inhalation of IB and placebo did not differ significantly. However, FEV1.0 and FEF25-75% after administration of IB increased in 4 out of 11 patients, and decreased in one. The lung volumes changed significantly in only a single case. This variable effect of inhaled IB in CF patients is in agreement with findings that have been observed for other substances with a "bronchodilatory" effect in patients with CF.

Publication types

  • Clinical Trial
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Adult
  • Atropine Derivatives / administration & dosage*
  • Child
  • Cystic Fibrosis / drug therapy*
  • Female
  • Forced Expiratory Volume / drug effects
  • Humans
  • Ipratropium / administration & dosage*
  • Male
  • Plethysmography, Whole Body*
  • Randomized Controlled Trials as Topic
  • Single-Blind Method
  • Spirometry*

Substances

  • Atropine Derivatives
  • Ipratropium